5243482025-10-012025-12-315243482025-04-012025-12-315243482025-10-012025-12-31in-capmkt:OtherExpenses1Member5243482025-04-012025-12-31in-capmkt:OtherExpenses1Member5243482025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15243482025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524348AARTIDRUGSNOTLISTEDINE767A01016AARTI DRUGS LIMITEDMain BoardEquity2025-04-012026-03-312026-02-032026-01-27INRLakhsQuarterlyThird quarterSingle segmentPharmaceuticals2026-02-0314:45:002026-02-0317:10:00Not applicable2025-10-012025-12-31AuditedConsolidated6017100000123000006029400000334520000022510000029610000033160000092900000179500000126880000057392000002902000000290200000-13490000019600000-115300000040550000000004055000003100000408600000405400000116000408300000273000912700000104.444.44004.444.44Notes : <BR> 1. The above results for the Quarter & Period ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 3rd February, 2026. <BR> 2. The Board of Directors have declared interim Dividend of Rs.2.00/-( Rupee Two) per Equity Share of Rs. 10/- each (20%) amounting to Rs.18,25,40,000 for the Period ended 31st December,2025. <BR> 3. As on December 31, 2025 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA. <BR> <BR> 4. The company has completed the buyback of 6,65,000 equity shares of face value of Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors’ fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.)(“Buyback Size”) on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs.10/- each. <BR> <BR> 5. On November 21, 2025, the Government of lndia notified the four Labour Codes - the Code on Wages, 2019, the lndustrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment has also published draft Central Rules and FAQs on aforesaid labour codes. The detailed impact assessment is currently in progress, necessary adjustments, if any, will be identified and appropriately accounted for in Q4 FY 2025–26. <BR> <BR> 6. Company has only one business segment i.e. pharmaceuticals. <BR> 7. The Company’s new manufacturing plant at Sayakha, Gujarat has commenced commercial production/operations w.e.f. September 4, 2025. <BR> <BR> 8. Figures for the previous Quarter have been regrouped or rearranged wherever necessary. <BR> 9. The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. <BR> <BR> FOR AARTI DRUGS LIMITED <BR> <BR> Sd/- <BR> Prakash M. Patil <BR> DIN: 00005618 <BR> (Chairman, Managing Director & CEO) <BR> <BR> <BR> Place: Mumbai <BR> Date: 3rd February, 20262025-04-012025-12-31AuditedConsolidated1845010000016300000184664000001076830000081770000097200000970300000255600000489300000366260000017061000000140540000001405400000-441000005270000086000000139680000000001396800000430000014011000001397200000-4510001401300000-2380009127000001015.315.30015.315.3Other Expenses1268800000Other Expenses3662600000Foreign currency translation reserve31000003100000Foreign currency translation reserve430000043000000031000004300000